The paradigm of first-line treatment of chronic lymphocytic leukaemia (CLL) is currently undergoing a radical change. On the basis of several randomised phase III trials showing prolongation of progression-free survival, chemoimmunotherapy is being replaced by treatment based on novel, orally available targeted inhibitors such as Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib or bcl-2 inhibitor venetoclax. However, the use of these agents may be associated with other disadvantages. First, with the exception of one trial in younger/fit patients, no studies have so far demonstrated benefit regarding the ultimate endpoint of overall survival. Second, oral inhibitors are extremely expensive and thus currently unavailable due to the absence of reimbursement in some countries. Third, treatment with ibrutinib and acalabrutinib necessitates long-term administration until progression; this may be associated with accumulation of late side effects, problems with patient compliance, and selection of resistant clones. Therefore, the identification of a subset of patients who could benefit from chemoimmunotherapy would be ideal. Current data suggest that patients with the mutated variable region of the immunoglobulin heavy chain (IGHV) achieve fairly durable remissions, especially when treated with fludarabine, cyclophosphamide, and rituximab (FCR) regimen. This review discusses current options for treatment-naïve patients with CLL.

4th Department of Internal Medicine Hematology Faculty of Medicine University Hospital Charles University 50005 Hradec Králové Czech Republic

Zobrazit více v PubMed

Dores G.M., Anderson W.F., Curtis R.E., Landgren O., Ostroumova E., Bluhm E.C., Rabkin C.S., Devesa S.S., Linet M.S. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology. Br. J. Haematol. 2007;139:809–819. doi: 10.1111/j.1365-2141.2007.06856.x. PubMed DOI

Watson L., Wyld P., Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union. Eur. J. Haematol. 2008;81:253–258. doi: 10.1111/j.1600-0609.2008.01114.x. PubMed DOI

Panovska A., Doubek M., Brychtova Y., Mayer J. Chronic lymphocytic leukemia and focusing on epidemiology and management in everyday hematologic practice: Recent data from the Czech Leukemia Study Group for Life (CELL) Clin. Lymphoma Myeloma Leuk. 2010;10:297–300. doi: 10.3816/CLML.2010.n.061. PubMed DOI

Weil C., Chodick G., Shalev V., Kan I., Afik R., Cohen R., Sail K., Herishanu Y. Epidemiology, longitudinal treatment patterns and outcomes of chronic lymphocytic leukemia in Israel. Leuk. Lymphoma. 2021;62:1136–1145. doi: 10.1080/10428194.2020.1858293. PubMed DOI

Dal Bo M., Bulian P., Bomben R., Zucchetto A., Rossi F.M., Pozzo F., Tissino E., Benedetti D., Bittolo T., Nanni P., et al. CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. Leukemia. 2016;30:2011–2018. doi: 10.1038/leu.2016.88. PubMed DOI

Weide R., Feiten S., Chakupurakal G., Friesenhahn V., Kleboth K., Koppler H., Lutschkin J., van Roye C., Thomalla J., Heymanns J. Survival improvement of patients with chronic lymphocytic leukemia (CLL) in routine care 1995–2017. Leuk. Lymphoma. 2020;61:557–566. doi: 10.1080/10428194.2019.1680840. PubMed DOI

Thurmes P., Call T., Slager S., Zent C., Jenkins G., Schwager S., Bowen D., Kay N., Shanafelt T. Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. Leuk. Lymphoma. 2008;49:49–56. doi: 10.1080/10428190701724785. PubMed DOI

Ko B.S., Chen L.J., Huang H.H., Chen H.M., Hsiao F.Y. Epidemiology, Treatment Patterns, and Survival of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in Taiwan, 2006–2015. Int. J. Clin. Pract. 2021:e14258. doi: 10.1111/ijcp.14258. PubMed DOI

Andres M., Feller A., Arndt V., The Nicer Working G. Trends of incidence, mortality and survival for chronic lymphocytic leukaemia/small lymphocytic lymphoma in Switzerland between 1997 and 2016: A population-based study. Swiss Med. Wkly. 2021;151:w20463. PubMed

da Cunha-Bang C., Simonsen J., Rostgaard K., Geisler C., Hjalgrim H., Niemann C.U. Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: A Danish population-based study of 10455 patients. Blood Cancer J. 2016;6:e499. doi: 10.1038/bcj.2016.105. PubMed DOI PMC

Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46:219–234. doi: 10.1182/blood.V46.2.219.219. PubMed DOI

Binet J.L., Auquier A., Dighiero G., Chastang C., Piguet H., Goasguen J., Vaugier G., Potron G., Colona P., Oberling F., et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48:198–206. doi: 10.1002/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V. PubMed DOI

Sylvan S.E., Asklid A., Johansson H., Klintman J., Bjellvi J., Tolvgard S., Kimby E., Norin S., Andersson P.O., Karlsson C., et al. First-line therapy in chronic lymphocytic leukemia: A Swedish nation-wide real-world study on 1053 consecutive patients treated between 2007 and 2013. Haematologica. 2019;104:797–804. doi: 10.3324/haematol.2018.200204. PubMed DOI PMC

Munoz-Novas C., Poza-Santaella M., Gonzalez-Gascon Y.M.I., Hernandez-Sanchez M., Rodriguez-Vicente A.E., Infante M.S., Heras C., Foncillas M.A., Marin K., Hernandez-Rivas J.M., et al. The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Brno Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. Biomed. Res. Int. 2018;2018:9506979. doi: 10.1155/2018/9506979. PubMed DOI PMC

Condoluci A., Terzi di Bergamo L., Langerbeins P., Hoechstetter M.A., Herling C.D., De Paoli L., Delgado J., Rabe K.G., Gentile M., Doubek M., et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135:1859–1869. doi: 10.1182/blood.2019003453. PubMed DOI

Smolej L., Turcsanyi P., Kubova Z., Zuchnicka J., Mihalyova J., Simkovic M., Vodarek P., Krcmeryova M., Mocikova H., Brejcha M., et al. External validation of International Prognostic Score for asymptomatic early stage chronic lymphocytic leukaemia and proposal of an alternative score. Br. J. Haematol. 2021;193:133–137. doi: 10.1111/bjh.17074. PubMed DOI

Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848–1854. doi: 10.1182/blood.V94.6.1848. PubMed DOI

Damle R.N., Wasil T., Fais F., Ghiotto F., Valetto A., Allen S.L., Buchbinder A., Budman D., Dittmar K., Kolitz J., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999;94:1840–1847. doi: 10.1182/blood.V94.6.1840. PubMed DOI

Dohner H., Stilgenbauer S., Benner A., Leupolt E., Krober A., Bullinger L., Dohner K., Bentz M., Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N. Engl. J. Med. 2000;343:1910–1916. doi: 10.1056/NEJM200012283432602. PubMed DOI

Parikh S.A., Strati P., Tsang M., West C.P., Shanafelt T.D. Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. Blood. 2016;127:1752–1760. doi: 10.1182/blood-2015-10-620864. PubMed DOI

Kreuzberger N., Damen J.A., Trivella M., Estcourt L.J., Aldin A., Umlauff L., Vazquez-Montes M.D., Wolff R., Moons K.G., Monsef I., et al. Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: A systematic review and meta-analysis. Cochrane Database Syst. Rev. 2020;7:CD012022. PubMed PMC

International CLL-IPI working group An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): A meta-analysis of individual patient data. Lancet Oncol. 2016;17:779–790. doi: 10.1016/S1470-2045(16)30029-8. PubMed DOI

Delgado J., Doubek M., Baumann T., Kotaskova J., Molica S., Mozas P., Rivas-Delgado A., Morabito F., Pospisilova S., Montserrat E. Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. Am. J. Hematol. 2017;92:375–380. doi: 10.1002/ajh.24660. PubMed DOI

Wierda W.G., O’Brien S., Wang X., Faderl S., Ferrajoli A., Do K.A., Cortes J., Thomas D., Garcia-Manero G., Koller C., et al. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007;109:4679–4685. doi: 10.1182/blood-2005-12-051458. PubMed DOI

Molica S., Giannarelli D., Mirabelli R., Levato L., Gentile M., Morabito F., Montserrat E. Reliability of six prognostic models to predict time-to-first-treatment in patients with chronic lymphocytic leukaemia in early phase. Am. J. Hematol. 2017;92:E91–E93. doi: 10.1002/ajh.24707. PubMed DOI

Morabito F., Tripepi G., Vigna E., Bossio S., D’Arrigo G., Martino E.A., Storino F., Recchia A.G., Fronza G., Di Raimondo F., et al. Validation of the Alternative International Prognostic Score-E (AIPS-E): Analysis of Binet stage A chronic lymphocytic leukemia patients enrolled into the O-CLL1-GISL protocol. Eur. J. Haematol. 2021;106:831–835. doi: 10.1111/ejh.13614. PubMed DOI

Rigolin G.M., Saccenti E., Guardalben E., Cavallari M., Formigaro L., Zagatti B., Visentin A., Mauro F.R., Lista E., Bassi C., et al. In chronic lymphocytic leukaemia with complex karyotype, major structural abnormalities identify a subset of patients with inferior outcome and distinct biological characteristics. Br. J. Haematol. 2018;181:229–233. doi: 10.1111/bjh.15174. PubMed DOI

Visentin A., Bonaldi L., Rigolin G.M., Mauro F.R., Martines A., Frezzato F., Pravato S., Gargarella L.R., Bardi M.A., Cavallari M., et al. The complex karyotype landscape in chronic lymphocytic leukemia allows to refine the risk of Richter syndrome transformation. Haematologica. 2021 doi: 10.3324/haematol.2021.278304. PubMed DOI PMC

Thompson P.A., O’Brien S.M., Wierda W.G., Ferrajoli A., Stingo F., Smith S.C., Burger J.A., Estrov Z., Jain N., Kantarjian H.M., et al. Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens. Cancer. 2015;121:3612–3621. doi: 10.1002/cncr.29566. PubMed DOI PMC

Herling C.D., Klaumunzer M., Rocha C.K., Altmuller J., Thiele H., Bahlo J., Kluth S., Crispatzu G., Herling M., Schiller J., et al. Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy. Blood. 2016;128:395–404. doi: 10.1182/blood-2016-01-691550. PubMed DOI

Hallek M., Cheson B.D., Catovsky D., Caligaris-Cappio F., Dighiero G., Dohner H., Hillmen P., Keating M., Montserrat E., Chiorazzi N., et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–2760. doi: 10.1182/blood-2017-09-806398. PubMed DOI

Baliakas P., Jeromin S., Iskas M., Puiggros A., Plevova K., Nguyen-Khac F., Davis Z., Rigolin G.M., Visentin A., Xochelli A., et al. Cytogenetic complexity in chronic lymphocytic leukemia: Definitions, associations, and clinical impact. Blood. 2019;133:1205–1216. doi: 10.1182/blood-2018-09-873083. PubMed DOI PMC

Rai K.R., Peterson B.L., Appelbaum F.R., Kolitz J., Elias L., Shepherd L., Hines J., Threatte G.A., Larson R.A., Cheson B.D., et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N. Engl. J. Med. 2000;343:1750–1757. doi: 10.1056/NEJM200012143432402. PubMed DOI

Leporrier M., Chevret S., Cazin B., Boudjerra N., Feugier P., Desablens B., Rapp M.J., Jaubert J., Autrand C., Divine M., et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood. 2001;98:2319–2325. doi: 10.1182/blood.V98.8.2319. PubMed DOI

Gellhorn A., Hyman G.A., Ultmann J.E. Chlorambucil in treatment of chronic lymphocytic leukemia and certain lymphomas. J. Am. Med. Assoc. 1956;162:178–183. PubMed

Galton D.A., Israels L.G., Nabarro J.D., Till M. Clinical trials of p-(di-2-chloroethylamino)-phenylbutyric acid (CB 1348) in malignant lymphoma. Br. Med. J. 1955;2:1172–1176. doi: 10.1136/bmj.2.4949.1172. PubMed DOI PMC

Eichhorst B.F., Busch R., Hopfinger G., Pasold R., Hensel M., Steinbrecher C., Siehl S., Jager U., Bergmann M., Stilgenbauer S., et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006;107:885–891. doi: 10.1182/blood-2005-06-2395. PubMed DOI

Catovsky D. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet. 2007;370:230–239. doi: 10.1016/S0140-6736(07)61125-8. PubMed DOI

Flinn I.W., Neuberg D.S., Grever M.R., Dewald G.W., Bennett J.M., Paietta E.M., Hussein M.A., Appelbaum F.R., Larson R.A., Moore D.F., Jr., et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J. Clin. Oncol. 2007;25:793–798. doi: 10.1200/JCO.2006.08.0762. PubMed DOI

Robak T., Blonski J.Z., Gora-Tybor J., Jamroziak K., Dwilewicz-Trojaczek J., Tomaszewska A., Konopka L., Ceglarek B., Dmoszynska A., Kowal M., et al. Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: Report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2) Blood. 2006;108:473–479. PubMed

Keating M.J., O’Brien S., Albitar M., Lerner S., Plunkett W., Giles F., Andreeff M., Cortes J., Faderl S., Thomas D., et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 2005;23:4079–4088. doi: 10.1200/JCO.2005.12.051. PubMed DOI

Hallek M., Fischer K., Fingerle-Rowson G., Fink A.M., Busch R., Mayer J., Hensel M., Hopfinger G., Hess G., von Grunhagen U., et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial. Lancet. 2010;376:1164–1174. doi: 10.1016/S0140-6736(10)61381-5. PubMed DOI

Bottcher S., Ritgen M., Fischer K., Stilgenbauer S., Busch R.M., Fingerle-Rowson G., Fink A.M., Buhler A., Zenz T., Wenger M.K., et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: A multivariate analysis from the randomized GCLLSG CLL8 trial. J. Clin. Oncol. 2012;30:980–988. doi: 10.1200/JCO.2011.36.9348. PubMed DOI

Fischer K., Bahlo J., Fink A.M., Goede V., Herling C.D., Cramer P., Langerbeins P., von Tresckow J., Engelke A., Maurer C., et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial. Blood. 2016;127:208–215. doi: 10.1182/blood-2015-06-651125. PubMed DOI

Thompson P.A., Tam C.S., O’Brien S.M., Wierda W.G., Stingo F., Plunkett W., Smith S.C., Kantarjian H.M., Freireich E.J., Keating M.J. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–309. doi: 10.1182/blood-2015-09-667675. PubMed DOI PMC

Fischer K., Cramer P., Busch R., Bottcher S., Bahlo J., Schubert J., Pfluger K.H., Schott S., Goede V., Isfort S., et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 2012;30:3209–3216. doi: 10.1200/JCO.2011.39.2688. PubMed DOI

Eichhorst B., Fink A.M., Bahlo J., Busch R., Kovacs G., Maurer C., Lange E., Koppler H., Kiehl M., Sokler M., et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): An international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928–942. doi: 10.1016/S1470-2045(16)30051-1. PubMed DOI

Kutsch N., Bahlo J., Robrecht S., Franklin J., Zhang C., Maurer C., De Silva N., Lange E., Weide R., Kiehl M.G., et al. Long Term Follow-up Data and Health-Related Quality of Life in Frontline Therapy of Fit Patients Treated With FCR Versus BR (CLL10 Trial of the GCLLSG) Hemasphere. 2020;4:e336. doi: 10.1097/HS9.0000000000000336. PubMed DOI PMC

Goede V., Fischer K., Busch R., Engelke A., Eichhorst B., Wendtner C.M., Chagorova T., de la Serna J., Dilhuydy M.S., Illmer T., et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N. Engl. J. Med. 2014;370:1101–1110. doi: 10.1056/NEJMoa1313984. PubMed DOI

Goede V., Fischer K., Engelke A., Schlag R., Lepretre S., Montero L.F., Montillo M., Fegan C., Asikanius E., Humphrey K., et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: Updated results of the CLL11 study. Leukemia. 2015;29:1602–1604. doi: 10.1038/leu.2015.14. PubMed DOI

Eichhorst B., Robak T., Montserrat E., Ghia P., Hillmen P., Hallek M., Buske C., Committee E.G. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2015;26(Suppl. S5):v78–v84. doi: 10.1093/annonc/mdv303. PubMed DOI

Hillmen P., Robak T., Janssens A., Babu K.G., Kloczko J., Grosicki S., Doubek M., Panagiotidis P., Kimby E., Schuh A., et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): A randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873–1883. doi: 10.1016/S0140-6736(15)60027-7. PubMed DOI

Michallet A.S., Aktan M., Hiddemann W., Ilhan O., Johansson P., Laribi K., Meddeb B., Moreno C., Raposo J., Schuh A., et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label MABLE study. Haematologica. 2018;103:698–706. doi: 10.3324/haematol.2017.170480. PubMed DOI PMC

Mulligan S.P., Gill D.S., Turner P., Renwick W.E.P., Harrup R., Latimer M., Mackinlay N., Berkahn L., Simpson D., Campbell P., et al. A Randomised Dose De-Escalation Safety Study of Oral Fludarabine, {+/-}Oral Cyclophosphamide and Intravenous Rituximab (OFOCIR) As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged >=65 Years—End of Recruitment Analysis of Response and Toxicity of the Australasian Leukaemia and Lymphoma Group (ALLG) and CLL Australian Research Consortium (CLLARC) CLL5 Study. ASH Annu. Meet. Abstr. 2012;120:436.

Smolej L., Brychtova Y., Cmunt E., Doubek M., Spacek M., Belada D., Simkovic M., Stejskal L., Zygulova I., Urbanova R., et al. Low-dose fludarabine and cyclophosphamide combined with rituximab in the first-line treatment of elderly/comorbid patients with chronic lymphocytic leukaemia/small lymphocytic lymphoma (CLL/SLL): Long-term results of project Q-lite by the Czech CLL Study Group. Br. J. Haematol. 2021;193:769–778. PubMed

Byrd J.C., Brown J.R., O’Brien S., Barrientos J.C., Kay N.E., Reddy N.M., Coutre S., Tam C.S., Mulligan S.P., Jaeger U., et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N. Engl. J. Med. 2014;371:213–223. doi: 10.1056/NEJMoa1400376. PubMed DOI PMC

Burger J.A., Tedeschi A., Barr P.M., Robak T., Owen C., Ghia P., Bairey O., Hillmen P., Bartlett N.L., Li J., et al. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2015;373:2425–2437. doi: 10.1056/NEJMoa1509388. PubMed DOI PMC

Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Samoilova O., Novak J., Ben-Yehuda D., et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:43–56. doi: 10.1016/S1470-2045(18)30788-5. PubMed DOI

Woyach J.A., Ruppert A.S., Heerema N.A., Zhao W., Booth A.M., Ding W., Bartlett N.L., Brander D.M., Barr P.M., Rogers K.A., et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. N. Engl. J. Med. 2018;379:2517–2528. doi: 10.1056/NEJMoa1812836. PubMed DOI PMC

Shanafelt T.D., Wang X.V., Kay N.E., Hanson C.A., O’Brien S., Barrientos J., Jelinek D.F., Braggio E., Leis J.F., Zhang C.C., et al. Ibrutinib-Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2019;381:432–443. doi: 10.1056/NEJMoa1817073. PubMed DOI PMC

O’Brien S., Jones J.A., Coutre S.E., Mato A.R., Hillmen P., Tam C., Osterborg A., Siddiqi T., Thirman M.J., Furman R.R., et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): A phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–1418. doi: 10.1016/S1470-2045(16)30212-1. PubMed DOI

Ahn I.E., Tian X., Wiestner A. Ibrutinib for Chronic Lymphocytic Leukemia with TP53 Alterations. N. Engl. J. Med. 2020;383:498–500. doi: 10.1056/NEJMc2005943. PubMed DOI PMC

Allan J.N., Shanafelt T., Wiestner A., Moreno C., O’Brien S.M., Braggio E., Liu E., Dean J.P., Lai D., Ahn I.E. Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) with 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials. Blood. 2020;136:23–24. doi: 10.1182/blood-2020-134431. DOI

Malcikova J., Tausch E., Rossi D., Sutton L.A., Soussi T., Zenz T., Kater A.P., Niemann C.U., Gonzalez D., Davi F., et al. ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-update on methodological approaches and results interpretation. Leukemia. 2018;32:1070–1080. doi: 10.1038/s41375-017-0007-7. PubMed DOI PMC

Edelmann J., Gribben J.G. Managing Patients with TP53-Deficient Chronic Lymphocytic Leukemia. J. Oncol. Pract. 2017;13:371–377. doi: 10.1200/JOP.2017.023291. PubMed DOI

Moia R., Boggione P., Mahmoud A.M., Kodipad A.A., Adhinaveni R., Sagiraju S., Patriarca A., Gaidano G. Targeting p53 in chronic lymphocytic leukemia. Expert Opin Ther Targets. 2020;24:1239–1250. doi: 10.1080/14728222.2020.1832465. PubMed DOI

Campo E., Cymbalista F., Ghia P., Jager U., Pospisilova S., Rosenquist R., Schuh A., Stilgenbauer S. TP53 aberrations in chronic lymphocytic leukemia: An overview of the clinical implications of improved diagnostics. Haematologica. 2018;103:1956–1968. doi: 10.3324/haematol.2018.187583. PubMed DOI PMC

Mato A.R., Nabhan C., Thompson M.C., Lamanna N., Brander D.M., Hill B., Howlett C., Skarbnik A., Cheson B.D., Zent C., et al. Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: A real-world analysis. Haematologica. 2018;103:874. doi: 10.3324/haematol.2017.182907. PubMed DOI PMC

Paydas S. Management of adverse effects/toxicity of ibrutinib. Crit. Rev. Oncol. Hematol. 2019;136:56–63. doi: 10.1016/j.critrevonc.2019.02.001. PubMed DOI

Lasica M., Tam C.S. Management of Ibrutinib Toxicities: A Practical Guide. Curr. Hematol. Malig. Rep. 2020;15:177–186. doi: 10.1007/s11899-020-00576-3. PubMed DOI

Stephens D.M., Byrd J.C. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019;133:1298–1307. doi: 10.1182/blood-2018-11-846808. PubMed DOI PMC

Burger J.A., Barr P.M., Robak T., Owen C., Ghia P., Tedeschi A., Bairey O., Hillmen P., Coutre S.E., Devereux S., et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787–798. doi: 10.1038/s41375-019-0602-x. PubMed DOI PMC

Ahn I.E., Underbayev C., Albitar A., Herman S.E., Tian X., Maric I., Arthur D.C., Wake L., Pittaluga S., Yuan C.M., et al. Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia. Blood. 2017;129:1469–1479. doi: 10.1182/blood-2016-06-719294. PubMed DOI PMC

Furman R.R., Sharman J.P., Coutre S.E., Cheson B.D., Pagel J.M., Hillmen P., Barrientos J.C., Zelenetz A.D., Kipps T.J., Flinn I., et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 2014;370:997–1007. doi: 10.1056/NEJMoa1315226. PubMed DOI PMC

Lampson B.L., Kim H.T., Davids M.S., Abramson J.S., Freedman A.S., Jacobson C.A., Armand P.A., Joyce R.M., Arnason J.E., Rassenti L.Z., et al. Efficacy results of a phase 2 trial of first-line idelalisib plus ofatumumab in chronic lymphocytic leukemia. Blood Adv. 2019;3:1167–1174. doi: 10.1182/bloodadvances.2018030221. PubMed DOI PMC

Lampson B.L., Kasar S.N., Matos T.R., Morgan E.A., Rassenti L., Davids M.S., Fisher D.C., Freedman A.S., Jacobson C.A., Armand P., et al. Idelalisib given front-line for treatment of chronic lymphocytic leukemia causes frequent immune-mediated hepatotoxicity. Blood. 2016;128:195–203. doi: 10.1182/blood-2016-03-707133. PubMed DOI PMC

Thompson P.A., Stingo F., Keating M.J., Ferrajoli A., Burger J.A., Wierda W.G., Kadia T.M., O’Brien S.M. Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016;122:2505–2511. doi: 10.1002/cncr.30069. PubMed DOI PMC

Ghia P., Pluta A., Wach M., Lysak D., Kozak T., Simkovic M., Kaplan P., Kraychok I., Illes A., de la Serna J., et al. ASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. J. Clin. Oncol. 2020;38:2849–2861. doi: 10.1200/JCO.19.03355. PubMed DOI

Danilov A.V., Persky D.O. Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies. Br. J. Haematol. 2021;193:15–25. doi: 10.1111/bjh.17184. PubMed DOI

Thompson P.A., Burger J.A. Bruton’s tyrosine kinase inhibitors: First and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL) Expert Opin. Investig. Drugs. 2018;27:31–42. doi: 10.1080/13543784.2018.1404027. PubMed DOI

Delgado J., Josephson F., Camarero J., Garcia-Ochoa B., Lopez-Anglada L., Prieto-Fernandez C., van Hennik P.B., Papadouli I., Gisselbrecht C., Enzmann H., et al. EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia. Oncologist. 2021;26:242–249. doi: 10.1002/onco.13685. PubMed DOI PMC

Sharman J.P., Egyed M., Jurczak W., Skarbnik A., Pagel J.M., Flinn I.W., Kamdar M., Munir T., Walewska R., Corbett G., et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): A randomised, controlled, phase 3 trial. Lancet. 2020;395:1278–1291. doi: 10.1016/S0140-6736(20)30262-2. PubMed DOI PMC

Byrd J.C., Hillmen P., Ghia P., Kater A.P., Chanan-Khan A.A.A., Furman R.R., O’Brien S.M., Yenerel M.N., Illés Á., Kay N.E. First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia. J. Clin. Oncol. 2021;39:7500. doi: 10.1200/JCO.2021.39.15_suppl.7500. PubMed DOI PMC

Byrd J.C., Woyach J.A., Furman R.R., Martin P., O’Brien S., Brown J.R., Stephens D.M., Barrientos J., Devereux S., Hillmen P., et al. Acalabrutinib in Treatment-Naive Chronic Lymphocytic Leukemia. Blood. 2021;137:3327–3338. doi: 10.1182/blood.2020009617. PubMed DOI PMC

Roberts A.W., Seymour J.F., Brown J.R., Wierda W.G., Kipps T.J., Khaw S.L., Carney D.A., He S.Z., Huang D.C., Xiong H., et al. Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J. Clin. Oncol. 2012;30:488–496. doi: 10.1200/JCO.2011.34.7898. PubMed DOI PMC

Kipps T.J., Eradat H., Grosicki S., Catalano J., Cosolo W., Dyagil I.S., Yalamanchili S., Chai A., Sahasranaman S., Punnoose E., et al. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk. Lymphoma. 2015;56:2826–2833. doi: 10.3109/10428194.2015.1030638. PubMed DOI PMC

Roberts A.W., Davids M.S., Pagel J.M., Kahl B.S., Puvvada S.D., Gerecitano J.F., Kipps T.J., Anderson M.A., Brown J.R., Gressick L., et al. Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2016;374:311–322. doi: 10.1056/NEJMoa1513257. PubMed DOI PMC

Stilgenbauer S., Eichhorst B., Schetelig J., Coutre S., Seymour J.F., Munir T., Puvvada S.D., Wendtner C.M., Roberts A.W., Jurczak W., et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–778. doi: 10.1016/S1470-2045(16)30019-5. PubMed DOI

Seymour J.F., Ma S., Brander D.M., Choi M.Y., Barrientos J., Davids M.S., Anderson M.A., Beaven A.W., Rosen S.T., Tam C.S., et al. Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: A phase 1b study. Lancet Oncol. 2017;18:230–240. doi: 10.1016/S1470-2045(17)30012-8. PubMed DOI PMC

Kater A.P., Seymour J.F., Hillmen P., Eichhorst B., Langerak A.W., Owen C., Verdugo M., Wu J., Punnoose E.A., Jiang Y., et al. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. J. Clin. Oncol. 2019;37:269–277. doi: 10.1200/JCO.18.01580. PubMed DOI

Seymour J.F., Kipps T.J., Eichhorst B., Hillmen P., D’Rozario J., Assouline S., Owen C., Gerecitano J., Robak T., De la Serna J., et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia. N. Engl. J. Med. 2018;378:1107–1120. doi: 10.1056/NEJMoa1713976. PubMed DOI

Fischer K., Al-Sawaf O., Bahlo J., Fink A.M., Tandon M., Dixon M., Robrecht S., Warburton S., Humphrey K., Samoylova O., et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med. 2019;380:2225–2236. doi: 10.1056/NEJMoa1815281. PubMed DOI

Al-Sawaf O., Zhang C., Tandon M., Sinha A., Fink A.M., Robrecht S., Samoylova O., Liberati A.M., Pinilla-Ibarz J., Opat S., et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188–1200. doi: 10.1016/S1470-2045(20)30443-5. PubMed DOI

Eichhorst B., Robak T., Montserrat E., Ghia P., Niemann C.U., Kater A.P., Gregor M., Cymbalista F., Buske C., Hillmen P., et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021;32:23–33. doi: 10.1016/j.annonc.2020.09.019. PubMed DOI

Wierda W.G., Byrd J.C., Abramson J.S., Bilgrami S.F., Bociek G., Brander D., Brown J., Chanan-Khan A.A., Chavez J.C., Coutre S.E., et al. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology. J. Natl. Compr. Canc. Netw. 2020;18:185–217. PubMed

Burger J.A., Sivina M., Jain N., Kim E., Kadia T., Estrov Z., Nogueras-Gonzalez G.M., Huang X., Jorgensen J., Li J., et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood. 2019;133:1011–1019. doi: 10.1182/blood-2018-10-879429. PubMed DOI PMC

Lambertini M., Del Mastro L., Gardin G., Levaggi A., Bighin C., Giraudi S., Pronzato P. Stevens-Johnson syndrome after treatment with bendamustine. Leuk Res. 2012;36:e153–e154. doi: 10.1016/j.leukres.2012.03.006. PubMed DOI

Carilli A., Favis G., Sundharkrishnan L., Hajdenberg J. Severe dermatologic reactions with bendamustine: A case series. Case Rep. Oncol. 2014;7:465–470. doi: 10.1159/000365324. PubMed DOI PMC

Visentin A., Deodato M., Mauro F.R., Autore F., Reda G., Vitale C., Molica S., Rigolin G.M., Imbergamo S., Scomazzon E., et al. A Scoring System to Predict the Risk of Atrial Fibrillation in Chronic Lymphocytic Leukemia and Its Validation in a Cohort of Ibrutinib-Treated Patients. Blood. 2018;132:3118. doi: 10.1182/blood-2018-99-114899. DOI

Yu J., Zhou Z., Tay-Sontheimer J., Levy R.H., Ragueneau-Majlessi I. Risk of Clinically Relevant Pharmacokinetic-Based Drug-Drug Interactions with Drugs Approved by the U.S. Food and Drug Administration Between 2013 and 2016. Drug Metab. Dispos. 2018;46:835–845. doi: 10.1124/dmd.117.078691. PubMed DOI

Weiss J., Gajek T., Kohler B.C., Haefeli W.E. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug-Drug Interactions. Pharmaceutics. 2016;8:5. doi: 10.3390/pharmaceutics8010005. PubMed DOI PMC

Shanafelt T.D., Borah B.J., Finnes H.D., Chaffee K.G., Ding W., Leis J.F., Chanan-Khan A.A., Parikh S.A., Slager S.L., Kay N.E., et al. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels. J. Oncol. Pract. 2015;11:252–258. doi: 10.1200/JOP.2014.002469. PubMed DOI

Chen Q., Jain N., Ayer T., Wierda W.G., Flowers C.R., O’Brien S.M., Keating M.J., Kantarjian H.M., Chhatwal J. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. J. Clin. Oncol. 2017;35:166–174. doi: 10.1200/JCO.2016.68.2856. PubMed DOI PMC

Lachaine J., Beauchemin C., Guinan K., Thebault P., Aw A., Banerji V., Fleury I., Owen C. Impact of Oral Targeted Therapy on the Economic Burden of Chronic Lymphocytic Leukemia in Canada. Curr. Oncol. 2021;28:332–345. doi: 10.3390/curroncol28010037. PubMed DOI PMC

Hilal T., Betcher J.A., Leis J.F. Economic Impact of Oral Therapies for Chronic Lymphocytic Leukemia-the Burden of Novelty. Curr. Hemato.l Malig. Rep. 2018;13:237–243. doi: 10.1007/s11899-018-0461-y. PubMed DOI

Sinha R., Redekop W.K. Cost-Effectiveness of Ibrutinib Compared with Obinutuzumab with Chlorambucil in Untreated Chronic Lymphocytic Leukemia Patients With Comorbidities in the United Kingdom. Clin. Lymphoma Myeloma Leuk. 2018;18:e131–e142. doi: 10.1016/j.clml.2017.12.005. PubMed DOI

Barnes J.I., Divi V., Begaye A., Wong R., Coutre S., Owens D.K., Goldhaber-Fiebert J.D. Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p. Blood Adv. 2018;2:1946–1956. doi: 10.1182/bloodadvances.2017015461. PubMed DOI PMC

Patel K.K., Isufi I., Kothari S., Davidoff A.J., Gross C.P., Huntington S.F. Cost-effectiveness of first-line vs third-line ibrutinib in patients with untreated chronic lymphocytic leukemia. Blood. 2020;136:1946–1955. doi: 10.1182/blood.2020004922. PubMed DOI

Davids M.S., Chatterjee A., Ravelo A., Shapouri S., Manzoor B.S., Sail K., Van de Wetering G., Hallek M. Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States. Blood. 2019;134:4741. doi: 10.1182/blood-2019-123706. PubMed DOI PMC

Rhodes J.M., Barrientos J.C. Chemotherapy-free frontline therapy for CLL: Is it worth it? Hematol. Am. Soc. Hematol. Educ. Program. 2020;2020:24–32. doi: 10.1182/hematology.2020000085. PubMed DOI PMC

Nowakowski G.S., Chiappella A., Gascoyne R.D., Scott D.W., Zhang Q., Jurczak W., Ozcan M., Hong X., Zhu J., Jin J., et al. ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. J. Clin. Oncol. 2021;39:1317–1328. doi: 10.1200/JCO.20.01366. PubMed DOI PMC

Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy

A comprehensive assessment of lymphocyte subsets, their prognostic significance, and changes after first-line therapy administration in patients with chronic lymphocytic leukemia